UroGen Pharma (URGN) Misses Q3 EPS by 1c

UroGen Pharma (NASDAQ: URGN) reported Q3 EPS of ($0.69), $0.01 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $27.48 million versus the consensus estimate of $33.19 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• PENN Entertainment (PENN) Reiterated at Market Outperform by Citizens as Relocation Announced
• PulteGroup (PHM) Reiterated at Market Outperform by Citizens Amid Normal Seasonality